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T
 
he goal of this panel was to identify key con-
tentious methodology issues in conducting
healthcare pharmacoeconomic evaluations in the
context of modeling studies. Its specific objectives
were to:
• identify and prioritize the key issues associated
with pharmacoeconomic modeling studies;
• identify a plan of action to resolve these issues;
• recommend next steps.
 
Background and Context
 
The primary purpose of modeling is to inform the
decision-making process [1,2]. One considerable
benefit of model formalization is that the uncer-
tainties and assumptions in this process are made
explicit and transparent.
To estimate costs and outcomes, existing data
are frequently insufficient to allow optimal health-
care decision-making. Each type of data (retro-
spective, prospective, meta-analysis, expert opin-
ion) has inherent strengths and weaknesses. Good
modeling practice incorporates the best available
evidence from all possible sources into a set of ex-
plicit parameters.
Although randomized clinical trials (RCTs) are
the gold standard for clinical research, they are
not always the best source of pharmacoeconomic
and outcomes data. RCT-based data collection is
often too costly, too time-consuming, or otherwise
not feasible. Sometimes modeling is the only ac-
cessible means to inform the clinical and health-
care decision-making process [3]. Although useful
for determining efficacy, data from RCTs have
significant limitations that sharply reduce their
usefulness for measuring the clinical outcomes and
economic consequences of drug use in actual pop-
ulations, including:
• limited duration of follow-up, often only
weeks or months;
• exclusion or under-representation of many
types of patients, especially the vulnerable;
• sample sizes too small to detect infrequent
events;
• atypical treatment settings, providers, and sub-
jects, which may influence compliance, event
rates, and costs;
• no assessment of healthcare utilization in rou-
tine care.
Mathematical modeling allows a rational and
scientific approach to overcoming these inherent
limitations of RCTs, using the best available evi-
dence.
 
Problem Statement
 
Currently there are two major obstacles confront-
ing modeling methodology. How do we optimize
the production of useful information for health
economic decision-makers, and how do we en-
courage its acceptance and use?
 
Issues
 
There are seven key areas of controversy in model-
ing methodology:
1. standardization;
2. making choices;
3. methodological development;
4. extending clinical studies and data issues;
5. effectiveness measures;
6. model validation;
7. peer review.
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Standardization
 
Comparability is the essence that determines the
preference of one intervention among alternatives;
differences in cost-effectiveness should reflect true
differences and not unnecessary differences in
method. This panel is not the first to recognize the
need for consensus on a set of standards that will
promote comparability of studies.
When resources are limited, how are they allo-
cated to programs important to the respective seg-
ments of society? The Panel on Cost-effectiveness
in Health and Medicine [4] recommended cost-
effectiveness analysis (CEA) from a societal per-
spective for policy decision-making on healthcare
resource allocation. They recommended a stan-
dardized reference case analysis across all CEAs
regardless of the intervention or outcome to pro-
vide the methodological uniformity that supports
comparability.
Besides health, real-world decisions include
other considerations such as access to services,
helping the most vulnerable, and other values im-
pacted by health decisions. Economic assessment
is only one of the tools decision-makers must use,
and the information it provides must be weighed
within the context of these other criteria. Values
outside of healthcare, which often influence choices
about health services, cannot be quantified in CEA.
Cost-benefit analysis (CBA), cost-effectiveness anal-
ysis (CEA), and cost-consequence analysis (CCA)
are complementary and the use of one does not
preclude the use of others in a study. Although
quality-adjusted life-years (QALYs) have the ad-
vantage that they measure changes in quality as
well as quantity of life, as currently defined, they
do not reflect perfectly everything about health
that matters to people, and perhaps never can.
The Panel on Cost-effectiveness in Health and
Medicine [4] made recommendations concerning
items of intervention and outcome to be included
in the numerator and the items for the denomina-
tor for a reference case scenario. Most are based
on reasonable facts, but some are arbitrarily cho-
sen and recommended for a reference case to
maintain consistency across studies. At present,
there is still no standard guide to good modeling
practices that can be used as a teaching or refer-
ence tool. No clear taxonomy of modeling tech-
niques has been documented, and there are no
standardized presentation formats.
 
Making Choices
 
Beyond standardization, in each study a number
of choices are made to fit the model to the re-
search question. Wherever choices are made, con-
servative values of all parameters should be cho-
sen, and the base case should represent the most
plausible assumptions.
When deciding on perspective, societal perspec-
tive, which includes all relevant cost and outcomes
consequences, is preferable. Certain options in de-
cision-making will be cost-effective from the soci-
etal perspective and not from the patient’s per-
spective. Resource allocation decisions are based
on cost-effectiveness evaluated at a specific level.
Decisions made at a higher level will affect the re-
source availability at lower levels. For example, at
the societal (governmental) level, policy decisions
on resource allocation are made based on the larg-
est proportion of the public affected. When indi-
vidual perspective is examined, that segment of
the population afflicted with a condition evalu-
ated as secondary for resource allocation purposes
would need to seek resources elsewhere, and their
cost-effectiveness model would have to take this
into account. Many healthcare providers find the
societal perspective irrelevant for their purposes; a
great deal of controversy continues concerning the
use of a narrower perspective and whether it
should only be presented accompanied by the so-
cietal perspective.
Choice of the costs of an intervention from the
governmental or societal perspective will take into
account the actual wholesale price (AWP) or dis-
counted wholesale price (DWP). From the patient
perspective there is a question of which price to
use. Are cost and price the same? Should the ac-
tual price paid be used, or should the discounted
retail price, the brand-name drug prices, or generic
drug prices be used? Each decision should be
transparent and based on sound rationale.
Choice of assumptions should be realistic, re-
flecting available data. No model perfectly repre-
sents reality; its validity rests on whether its as-
sumptions are reasonable in light of the needs and
purposes of the decision-maker and whether after
close examination its implications make sense. In
making discounting decisions, both costs and ben-
efits should be done at the same rate, a standard
of care should be used as the appropriate compar-
ator, and the time horizon should be the duration
of time a drug can be expected to meaningfully
impact the patient’s health.
 
Methodological Development
 
A limitation of decision-tree models is that they
are not well suited to represent recurrent events
over time [5,6]. In chronic diseases, outcome
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events such as complications of the disease or its
treatment, recurrence of disease, and mortality,
are confounded frequently during a lifetime, with
probabilities that change with time, age, and
health status. Rather than model each event as a
separate branch of a complex decision tree, health
economic modeling methodology has room for
maturation and refinement to allow more efficient
mathematical representations of such events. Cur-
rent alternatives in development include state-
transition models, difference equations, determin-
istic models, and stochastic models, or discrete
event simulations [7].
 
Extending Clinical Studies and Data Issues
 
Some degree of modeling is usually necessary to as-
sess clinical outcomes and economic consequences
beyond the necessarily limited parameters of a clini-
cal trial, and modeling represents the only appropri-
ate analytic approach to estimate healthcare utiliza-
tion, practice patterns, and other costs associated
with observations across defined geographic areas
or treatment settings, such as from country to
country, health management organization to fee-
for-service, or government to private [8].
Many cost and outcomes distributions violate
standard normality assumptions, and outliers can
have a major impact on results. There are substan-
tial problems with aggregation bias when costs
and outcomes are averaged or combined for large
groups such as disease related group (DRG) reim-
bursement levels or average length of stay. As far
as possible, data should be analyzed at the individ-
ual level for both costs and outcomes. Many still
question whether RCT data should be made avail-
able to support individual-level analyses.
Analysis of data from all study subjects is nec-
essary to support interpretation of clinical trial
data for pharmacoeconomic modeling. However,
although intent-to-treat analysis is important, it is
not necessarily the only way to analyze RCT data
for modeling.
 
Effectiveness Measures
 
Several other issues arise in the estimation of effec-
tiveness for modeling methodology: specification
of survival parameters; use of disease-specific or
total mortality data; modeling patient characteris-
tics; using models to vary program parameters;
use of modeling to address lead-time and length
biases; estimating uncertainties. The techniques
that exist to deal with these issues are serviceable,
but have not yet achieved state-of-the-art status or
standardization.
Parameter uncertainty is generally handled on a
qualitative basis with either univariate or multi-
variate sensitivity analysis or max-min analysis, or
quantified using statistical approaches such as the
Delta method, joint confidence intervals, boot-
strapped estimates, or Monte Carlo simulation.
No proven method exists to validate structure un-
certainty in a model due to either the parameter
values assigned or to the mathematical form in
which the parameter values are combined, except
to compute C/E ratio estimates for each alterna-
tive structural assumption and examine appropri-
ateness of the results. Even process uncertainty is
an unknown. Would any two analysts follow the
same model, or if the same problem were posed to
an analyst a second time (without awareness of
the first result), would the same model be fol-
lowed?
While it is generally agreed that proper applica-
tion of multivariate sensitivity analysis is neces-
sary, there is ongoing controversy over its value.
 
Model Validation
 
As a mathematical device, and as a potentially im-
portant component of healthcare decision-mak-
ing, credibility of a pharmacoeconomic model
rests on its validity. Besides an estimate of the
range of uncertainty of its parameters, each model
should be shown to demonstrate face validity and
predictive validity. Wherever possible, models
should be validated against other data sets.
 
Peer Review of Models
 
To ensure the quality and enhance the acceptabil-
ity of pharmacoeconomic modeling, all models
should undergo systematic peer review before pre-
sentation. This could be a standardized audit of
the structure, process, and validity of the model
and would ensure that all salient model results are
transparent. A technical peer review would neces-
sitate passing an electronic copy of the computer
model to the reviewer(s), which raises questions
about the handling of proprietary property and
confidentiality.
 
Recommendations and Next Steps
 
The following recommendations address the seven
issues identified:
• Working towards general acceptance that mod-
eling of both costs and effectiveness is a valid
and often essential method to inform health-
care decision-making will be necessary to es-
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tablish modeling as an invaluable healthcare
decision-making tool.
• Because the usefulness of modeling studies is
necessarily based on comparability, it is impor-
tant to assemble a consensus of opinion on
standardized practices and policies.
• Once standardization has been achieved, a ref-
erence text of these practices should be pre-
pared and disseminated.
• Pharmacoeconomic claims based on these gen-
erally accepted modeling approaches should be
permitted by regulatory agencies, and should
always include transparency and appropriate
disclaimers such as: “This economic analysis is
based on assumptions and simulations con-
cerning the efficacy of [drug name] that meet
FDA criteria for claims of efficacy.” Any
model that relies on assumptions about a
drug’s efficacy that are not based on data from
RCTs must prominently disclose such limita-
tion in any promotion.
• We recommend that as an independent profes-
sional association of pharmacoeconomic and
outcomes researchers, ISPOR take the initia-
tive of assembling a balanced international
panel of thought-leaders and end-users in the
field of modeling to develop a package of gen-
erally accepted modeling practices, building
upon previously published work.
• Once these practices have been documented,
the goal of ISPOR should be to encourage all
stakeholders (professional societies, manufac-
turing associations, journals, government agen-
cies, regulatory agencies, payers, and healthcare
providers) to accept these as standards and to
endorse their use.
 
Summary
 
Mathematical modeling is a potentially invaluable
tool to assist the health economic decision-making
process. It serves a unique methodological func-
tion. However, its practical value is currently lim-
ited by:
• insufficient standardization;
• meager documentation of practices and poli-
cies;
• no systematic quality surveillance;
• a low level of acceptance by regulatory agen-
cies and end users.
We hope that by supporting the development of
standard practices, policy consensus, and a peer
review process, the use and acceptability of health
economic modeling will be potentiated.
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